Serum Fibrinogen-Like Protein 1 Levels in Obese Patients Before and After Laparoscopic Sleeve Gastrectomy: A Six-Month Longitudinal Study

References

• Jaacks LM, Vandevijvere S, Pan A, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7(3):231–240. doi:10.1016/S2213-8587(19)30026-9
   PubMed Web of Science ®Google Scholar
• Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018;39(2):79–132. doi:10.1210/er.2017-00253
   PubMed Web of Science ®Google Scholar
• Bray GA, Fruhbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016;387(10031):1947–1956. doi:10.1016/S0140-6736(16)00271-3
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–887.
   PubMed Web of Science ®Google Scholar
• Chen G, Zhang GX, Peng BQ, Cheng Z, Du X. Roux-En-Y Gastric bypass versus sleeve gastrectomy plus procedures for treatment of morbid obesity: systematic review and meta-analysis. Obes Surg. 2021;31(7):3303–3311. doi:10.1007/s11695-021-05456-0
   Web of Science ®Google Scholar
• Rao RS, Yanagisawa R, Kini S. Insulin resistance and bariatric surgery. Obes Rev. 2012;13(4):316–328. doi:10.1111/j.1467-789X.2011.00955.x
   PubMed Web of Science ®Google Scholar
• Faramia J, Ostinelli G, Drolet-Labelle V, Picard F, Tchernof A. Metabolic adaptations after bariatric surgery: adipokines, myokines and hepatokines. Curr Opin Pharmacol. 2020;52:67–74. doi:10.1016/j.coph.2020.06.005
   PubMed Web of Science ®Google Scholar
• Lim J, Park HS, Lee SK, Jang YJ, Lee YJ, Heo Y. Longitudinal changes in serum levels of angiopoietin-like protein 6 and selenoprotein P after gastric bypass surgery. Obes Surg. 2016;26(4):825–832. doi:10.1007/s11695-015-1808-2
   Web of Science ®Google Scholar
• Yang PJ, Ser KH, Lin MT, et al. Diabetes associated markers after bariatric surgery: fetuin-A, but not matrix metalloproteinase-7, is reduced. Obes Surg. 2015;25(12):2328–2334. doi:10.1007/s11695-015-1688-5
   Web of Science ®Google Scholar
• Hosseinzadeh A, Roever L, Alizadeh S. Surgery-induced weight loss and changes in hormonally active fibroblast growth factors: a systematic review and meta-analysis. Obes Surg. 2020;30(10):4046–4060. doi:10.1007/s11695-020-04807-7
   Web of Science ®Google Scholar
• Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367–1393. doi:10.1210/er.2019-00034
   PubMed Web of Science ®Google Scholar
• Demchev V, Malana G, Vangala D, et al. Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization. PLoS One. 2013;8(3):e58084. doi:10.1371/journal.pone.0058084
   PubMed Web of Science ®Google Scholar
• de Oliveira Dos Santos AR, de Oliveira Zanuso B, Miola VFB, et al. Adipokines, myokines, and hepatokines: crosstalk and metabolic repercussions. Int J Mol Sci. 2021;22(5):2639. doi:10.3390/ijms22052639
   PubMed Web of Science ®Google Scholar
• Yan J, Yu YL, Wang N, et al. LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma. Oncogene. 2004;23(10):1939–1949. doi:10.1038/sj.onc.1207306
   Web of Science ®Google Scholar
• Wu HT, Lu FH, Ou HY, et al. The role of hepassocin in the development of non-alcoholic fatty liver disease. J Hepatol. 2013;59(5):1065–1072. doi:10.1016/j.jhep.2013.06.004
   Web of Science ®Google Scholar
• Wu HT, Ou HY, Hung HC, et al. A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes. Diabetologia. 2016;59(8):1732–1742. doi:10.1007/s00125-016-3991-7
   PubMed Web of Science ®Google Scholar
• Kang L, Li HY, Ou HY, et al. Role of placental fibrinogen-like protein 1 in gestational diabetes. Transl Res. 2020;218:73–80. doi:10.1016/j.trsl.2020.01.001
   Web of Science ®Google Scholar
• Wu HT, Chen SC, Fan KC, et al. Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity. FASEB J. 2020;34(2):2958–2967. doi:10.1096/fj.201901925R
   PubMed Web of Science ®Google Scholar
• Jung TW, Chung YH, Kim HC, Abd El-Aty AM, Jeong JH. Hyperlipidemia-induced hepassocin in the liver contributes to insulin resistance in skeletal muscle. Mol Cell Endocrinol. 2018;470:26–33. doi:10.1016/j.mce.2017.10.014
   Web of Science ®Google Scholar
• Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Obes Surg. 2017;27(1):2–21. doi:10.1007/s11695-016-2457-9
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–1495. doi:10.2337/diacare.27.6.1487
   PubMed Web of Science ®Google Scholar
• Dilimulati D, Cai M, Lin Z, et al. Correlation between sex hormones and non-alcoholic fatty liver disease before and after laparoscopic sleeve gastrectomy. Obes Surg. 2021;31(11):4901–4910. doi:10.1007/s11695-021-05663-9
   Web of Science ®Google Scholar
• Borges-Canha M, Neves JS, Mendonca F, et al. Beta cell function as a baseline predictor of weight loss after bariatric surgery. Front Endocrinol. 2021;12:714173. doi:10.3389/fendo.2021.714173
   Web of Science ®Google Scholar
• Huang RL, Li CH, Du YF, et al. Discovery of a role of the novel hepatokine, hepassocin, in obesity. Biofactors. 2020;46(1):100–105. doi:10.1002/biof.1574
   Web of Science ®Google Scholar
• Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–873. doi:10.1016/j.jhep.2017.06.003
   PubMed Web of Science ®Google Scholar
• Stefan N, Haring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9(3):144–152. doi:10.1038/nrendo.2012.258
   PubMed Web of Science ®Google Scholar
• Poloczek J, Kazura W, Kwasnicka E, Gumprecht J, Jochem J, Stygar D. Effects of bariatric surgeries on fetuin-A, selenoprotein P, angiopoietin-like protein 6, and fibroblast growth factor 21 concentration. J Diabetes Res. 2021;2021:5527107. doi:10.1155/2021/5527107
   Web of Science ®Google Scholar
• Tsai IT, Hung WC, Lu YC, et al. Circulating hepassocin level in patients with stable angina is associated with fatty liver and renal function. Int J Med Sci. 2021;18(1):1–7. doi:10.7150/ijms.50646
   Web of Science ®Google Scholar
• Yang Y, Liu X, Chen H, et al. HPS protects the liver against steatosis, cell death, inflammation, and fibrosis in mice with steatohepatitis. FEBS J. 2022. doi:10.1111/febs.16430
   Web of Science ®Google Scholar
• Stygar D, Piglowski W, Chelmecka E, et al. Changes in liver gene expression and plasma concentration of rbp4, fetuin-A, and Fgf21 in sprague-dawley rats subjected to different dietary interventions and bariatric surgery. Biomed Res Int. 2018;2018:3472190. doi:10.1155/2018/3472190
   Web of Science ®Google Scholar
• Gao M, Yan H, Yin RH, et al. Hepassocin is required for hepatic outgrowth during zebrafish hepatogenesis. Biochem Bioph Res Co. 2015;463(3):466–471. doi:10.1016/j.bbrc.2015.05.121
   Web of Science ®Google Scholar
• Li CY, Cao CZ, Xu WX, et al. Recombinant human hepassocin stimulates proliferation of hepatocytes in vivo and improves survival in rats with fulminant hepatic failure. Gut. 2010;59(6):817–826. doi:10.1136/gut.2008.171124
   Web of Science ®Google Scholar
• Ou HY, Wu HT, Lin CH, et al. The hepatic protection effects of hepassocin in hyperglycemic crisis. J Clin Endocrinol Metab. 2017;102(7):2407–2415. doi:10.1210/jc.2016-3287
   PubMed Web of Science ®Google Scholar
• Lima WG, Martins-Santos MES, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism. Biochimie. 2015;116:17–23. doi:10.1016/j.biochi.2015.06.025
   PubMed Web of Science ®Google Scholar
• De Bandt JP, Jegatheesan P, Tennoune-El-Hafaia N. Muscle loss in chronic liver diseases: the example of nonalcoholic liver disease. Nutrients. 2018;10:9. doi:10.3390/nu10091195
   Web of Science ®Google Scholar
• Xie D, Zhao H, Lu J, et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling. Am J Physiol Endocrinol Metab. 2021;320(6):E1032–E1043. doi:10.1152/ajpendo.00518.2020
   PubMed Web of Science ®Google Scholar